| DATE: August 1, 2024 |
| --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Strawpoll sent with these minutes |
| Introduction of new staff | We have added 3 new individuals that will be supporting CPIC guideline development. See slides for pictures and more information. |  |
| Guidelines in-progress | Guidelines* *CYP2D6*/Beta-blockers – published (https://cpicpgx.org/guidelines/cpic-guideline-for-beta-blockers/)
* *CYP2B6*/Methadone – published (https://cpicpgx.org/guidelines/cpic-guideline-for-methadone-based-on-cyp2b6-genotype/)
* *CYP3A5*/Tacrolimus – In evidence review.
* *CYP2D6*/Antipsychotics – In evidence review; the authors are discussing adding more genes
* *NAT2*/Hydralazine – working on recommendations
* UGT1A1/irinotecan- On hold because of re-prioritization for DPYD and TPMT/NUDT15 updates (new evidence that might affect recommendation)
* DPYD/fluoropyrimidines- Evidence review underway
* TPMT-NUDT15/thiopurines update-Evidence review underway
* CYP2D6/ondansetron-Authorship plan underway

Allele function expert panel* NAT2-evidence review underway
* CYP3A5 is complete; will add CYP3A4 if needed
* NUDT15/TPMT-first meeting soon
* DPYD-evidence review underway
 | Kelly will continue to update |
| Register for PGRN meeting | PGRN 2024 Scientific meeting (September 23rd-25th) registration open and agenda posted (<https://www.pgrn.org/page-18215>)  |  |
| AMP DPYD recommendations | Vicky Pratt reviewed [AMP’s recent DPYD genotyping recommendations](https://www.sciencedirect.com/science/article/pii/S1525157824001545?via%3Dihub). Slides attached with minutes  |  |